What does the evidence say? When Canada's health care decision-makers need to know, they ask CADTH. We're a trusted source for evidence on drugs and medical devices. How can we help you with your next decision?
Tisagenlecleucel (Kymriah) for Pediatric Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adults with relapsed or refractory diffuse larg... Published on: January 15, 2019
Access to and Availability of Non-Pharmacological Treatments for Chronic Non-Cancer Pain in Canada: An Environmental Scan CADTH conducted an Environmental Scan to understand the current context around access to and the availability of non-pharmacological trea... Published on: November 21, 2018
International Policies on the Appropriate Use of Biosimilar Drugs A number of biosimilar drugs are emerging in Canada. As these drugs cannot be considered direct replacements for the innovator biologics ... Published on: September 18, 2018
2019 CADTH Symposium CADTH will be hosting its annual Symposium at the Shaw Centre in Edmonton, Alberta, from April 14 to 16, 2019. For more information, plea... Event Date: April 14, 2019 - April 16, 2019
Call for Patient Input and Clinical Experts: dolutegravir/lamivudine CADTH has received the following notice(s) of pending drug submission(s). Brand name TBC Generic name dolutegravir / lamivudine Manufact... Published on: January 23, 2019
Call for Feedback: Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation A document related to the project entitled Optimal Use of Minimally Invasive Glaucoma Surgery: Recommendation is now available for feedba... Published on: January 22, 2019
New at CADTH - January 2019 Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news ... Published on: January 9, 2019
